| 0.44 | 1.13% |
| SLXP NASDAQSalix Pharmaceuticals Ltd. | |
Market Cap 2.286B Book Value 6.472 EBITDA -12.0M PEG Ratio 29.94 EPS -1.178 P/B Ratio 6.04 Short Ratio 6.50 Index Membership S&P Sector Healthcare Full Time Employees 395 Profile Get Profile for: Drug Related Products Open 39.06 High 39.75 Low 38.98 Volume 205.9 K Target Price 50.60 Current EPS -1.178 This Year EPS 0.03 Next Year EPS 1.55 This Year PE 1303.33 Next Year PE 25.23 | Symbol | SLXP | | Name | Salix Pharmaceuticals Ltd. | | Type | Stock | | Country | United States | | Exchange | NASDAQ |
| | Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. |
Company Summary more  Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars?Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Top Stories| | 2010-08-31 |  | |
| | |
Earnings Postmortem for NBTY; NTY, PRGO, SLXP, HLF
Learning Markets - Aug 31, 2010
NBTY, Inc. (NTY) [Chart - Analysis - News] released its most recent earnings statement about a month ago on Wednesday, July 28th. NBTY, Inc. beat expectations with a profit of $1.03 per share---21 ...
2010-08-31 |  | |
| | | 2010-08-30 |  | |
| | | 2010-08-30 |  | |
|
| | A rally among airlines and a surprise jump in factory orders pushed US stocks higher in choppy trading on Tuesday. 2010-09-02 |  | |
|
Community Discussions | | | 0.02 | 0.28% |
| NAII NGMNatural Alternatives Internati | |
Market Cap 51.2M Book Value 4.253 EBITDA 8.1M EPS 0.71 P/E 10.14 P/B Ratio 1.69 Short Ratio 0.40 Sector Healthcare Full Time Employees 181 Profile Get Profile for: Drug Related Products Open 7.15 High 7.26 Low 6.48 Volume 3.3 K Current EPS 0.71 Current PE 10.14 | Symbol | NAII | | Name | Natural Alternatives International Inc. | | Type | Stock | | Country | United States | | Exchange | NGM |
| | Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. |
Company Summary more  Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print ... Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print media and the Internet distribution channels. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. The company was founded in 1980 and is headquartered in San Marcos, California. Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print ... Top Stories| | 2010-08-31 |  | |
| | | 2010-08-12 |  | |
| | | 2009-11-11 |  | |
| | | 2008-11-13 |  | |
|
Community Discussions |